Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project

Dementia

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Alzheimers Dement.

Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer's Disease Neuroimaging Initiative, the DESCRIPA working group, the INSIGHT-preAD study group, on behalf of the SCD-I working group, van der Flier WM

doi: 10.1016/j.jalz.2018.10.003.

Multiple Sclerosis

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

J Neurol.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group

doi: 10.1007/s00415-018-9070-x.

Aging and Cognitive FunctionsAlzheimer’s Disease

Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology

JAMA Neurol.

Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, Landau SM, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative

doi: 10.1001/jamaneurol.

Aging and Cognitive FunctionsDementia

Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression

J Alzheimers Dis.

Scheltens NME, Tijms BM, Heymans MW, Rabinovici GD, Cohn-Sheehy BI, Miller BL, Kramer JH, Wolfsgruber S, Wagner M, Kornhuber J, Peters O, Scheltens P, van der Flier WM, Amsterdam Dementia Cohort, Alzheimer’s Disease Neuroimaging Initiative, German Dementia Competence Network, University of San Francisco Memory and Aging Center

doi: 10.3233/JAD-171088.

Multiple Sclerosis

Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

Autoimmun Rev.

Ziemssen T, Medin J, Anne-Marie Couto C, Mitchell CR

doi: 10.1016/j.autrev.2017.02.007.

Alzheimer’s Disease

Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport

JAMA Neurol.

Kunkle BW, Vardarajan BN, Naj AC, Whitehead PL, Rolati S, Slifer S, Carney RM, Cuccaro ML, Vance JM, Gilbert JR, Wang LS, Farrer LA, Reitz C, Haines JL, Beecham GW, Martin ER, Schellenberg GD, Mayeux RP, Pericak-Vance MA

doi: 10.1001/

Aging and Cognitive FunctionsAlzheimer’s Disease

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease

Alzheimers Dement.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C; Dominantly Inherited Alzheimer Network (DIAN)

doi: 10.1016/j.jalz.2018.06.3059.

Targeting prodromal Alzheimer's disease: too late for prevention?

Lancet Neurol.

Yassine HN

doi: 10.1016/

Alzheimer’s Disease

Prediction of Alzheimer's disease dementia with MRI beyond the short-term: Implications for the design of predictive models

Neuroimage Clin.

Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, Ruibal Á, Aguiar P, Alzheimer's Disease Neuroimaging Initiative.

doi: 10.1016/j.nicl.2019.101837.

Related content